Evaluation of the efficacy of Sofosbuvir/Daclatasvir regimen in treating HCV/HIV co-infected patients

https://doi.org/10.52322/jocmbmh.07.en.07

Introduction: One of the most commonly recommended DAAs in the treatment guidelines for chronic hepatitis C is daclatasvir (DAC) in combination with sofosbuvir (SOF).

Objectives: To evaluate the treatment effects of Sofosbuvir/Dalatasvir regimen in patients with chronic HCV infection with HIV co-infection at Dong Da General Hospital, Hanoi.

Material and Methods: Descriptive and prospective studies on 60 HCV/HIV co-infected subjects receiving Sofosbuvir/Daclatasvir regimen from June 2018 to May 2020.

Result: 100% of patients with clinical stage 1, clinical symptoms and opportunistic infections changed significantly after 4 weeks of treatment, 100% of follow-up patients had no clinical manifestations and opportunistic infections at T4 and stabilization later. Mean CD4 cell count at the end of follow-up increased significantly with the start of treatment (p<0.01). HIV- RNA load at the end of follow-up of cirrhosis and hepatitis 100% group reached levels below detection threshold. The sustained viral response after 12 weeks of treatment (SVR 12) of both groups was 100%. The mean value of liver enzymes after treatment decreased compared to the time of T0 (p<0.01); and 100% of patients had normal liver enzymes at time of SVR12. APRI index decreased significantly compared to the time of T0 (p<0.01); based on Fibroscan results, the rate of hepatitis and cirrhosis is unchanged.

Conclusion: SVR12 outcomes of HCV/HIV co-infected patients showed a good response with Sofosbuvir/Daclatasvir regimen.

File toàn văn

Bài báo liên quan

• A systematic review of scope of studies related to antimicrobial resistance and antibiotic use among children in Vietnam
• Ultrasound in the diagnosis of infectious and tropical diseases: A literature review
• A narrative review of clinical management of Clostridium difficile in hospital setting
• Clinical manifestations, laboratory findings, antimicrobial susceptibility and outcomes of Enterococcus blood stream infection at Bach Mai Hospital and National Hospital for Tropical Diseases
• Clinical characteristics, laboratory findings and outcomes of Toxoplasma gondii infection in HIV/AIDS patients at Bach Mai Hospital
• Mortality rate and causes of death among HIV patients at Bach Mai Hospital: A retrospective analysis from 2009-2018
• HIV-associated neurocognitive disorder among long-term HIV/AIDS patients under antiretroviral therapy at Bach Mai Hospital
• Evaluation of the efficacy of Sofosbuvir/Daclatasvir regimen in treating HCV/HIV co-infected patients
• Clinical, laboratory characteristics, and outcomes of murine typhus patients in Vietnam: A multicenter prospective cohort study
• Low prevalence of SARS-CoV-2 antibodies among high-risks health care workers at a tertiary referral hospital in Vietnam
• Clinical features and factors associated with outcomes of COVID-19 patients in Vietnam: a retrospective observation analysis